Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 2/20 | 0.47 |
| ▸ | SKP1 | P63208 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | DTYMK | P23919 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583906 | 0.80 | GPR119 (0.43) | GBA1GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL3159336 | 0.80 | GAA (0.60) | ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL13118663 | 0.77 | GPR119 (0.56) | GBA1GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL82779 | 0.77 | MAPT (0.50) | GPR119ALDH1A1LMNAMAPTCKS1B | |
| SCHEMBL2023366 | 0.77 | SMN1; SMN2 (0.72) | GBA1GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL27237943 | 0.77 | LMNA (0.46) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL5573222 | 0.77 | MAPT (0.76) | GPR119ALDH1A1LMNAMAPTNAMPT | |
| SCHEMBL25003025 | 0.76 | MEN1 (0.50) | GPR119ALDH1A1LMNAMAPTCKS1B | |
| SCHEMBL985065 | 0.76 | GPR119 (0.55) | GPR119ALDH1A1LMNAMAPTNAMPT | |
| SCHEMBL23306486 | 0.76 | HRH3 (0.54) | GBA1GPR119ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368115-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHUJING BIOPHARMA CO., LTD (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4382521-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shujing Biopharma Co., Ltd (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-117769545-A | Tri-fused ring derivative-containing regulator, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023011608-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2023011608-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368115-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TPH1, TPH2, GAP43 | GBA1 3639/4885GPR119 76/4885ALDH1A1 2405/4885 |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | GBA1 2768/4885GPR119 1086/4885ALDH1A1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.